Inhaled Interferon Beta Formulation Decreases Severity Risk by 79% in COVID-19 Patients
A clinical trial of an inhaled formulation of interferon beta in hospitalized COVID-19 patients has shown that who received the drug had a 79% lower risk of developing severe disease compared to placebo and were more than twice as likely to recover from COVID-19 as those on placebo. More...21 Jul 2020
Identification of Genetic Factors Influencing COVID-19 Susceptibility Could Pave Way for Personalized Treatment
Researchers at the Cleveland Clinic (Cleveland, OH, USA) have identified genetic factors that may influence susceptibility to COVID-19, which could guide personalized treatment. More...21 Jul 2020
New Monoclonal Antibodies Show Promise in Fight Against COVID-19
Researchers at Vanderbilt University Medical Center (Nashville, TN, USA) have identified potently neutralizing antibodies that are showing promise as a potential therapy for preventing and treating COVID-19 in preclinical studies. More...21 Jul 2020
Oxford COVID-19 Vaccine Produces Strong Dual Immune Response in 90% of People After One Dose
The University of Oxford (Oxford, UK) has published results of the Phase 1/2 trial of its COVID-19 vaccine candidate that indicate no early safety concerns and strong responses induced in both parts of the immune system. More...21 Jul 2020
Linear-DNA Forms of COVID-19 Vaccine Candidates Show Strong Antibody and T-Cell Responses in Preclinical Trials
A group of linear-DNA forms of COVID-19 vaccine candidates under development has yielded strong antibody and T-cell responses even at very low doses of linear DNA in preclinical trials, raising the potential of effective dosing empowering global utility. More...20 Jul 2020
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Ultrasonic Cleaner
Cole-Parmer Ultrasonic Cleaner with Digital Timer
New
Hospital Data Analytics Software
OR Companion
In Other News
Russia to Produce 30 Million Doses of Experimental COVID-19 Vaccine in 2020
Scientists Use Machine Learning Algorithm to Identify Six Types of COVID-19 with Distinctive Symptoms
Quest Diagnostics’ SARS-CoV-2 rRT-PCR Test Becomes First COVID-19 Diagnostic Test to Receive FDA EUA for Sample Pooling
Scientists Decode How Coronavirus Evades Host Cell Defense
Oxford University’s Rapid COVID-19 Test Detects SARS-CoV-2 Within 30-45 Minutes
FDA-Approved Blood Thinner Could Be Used as Decoy to Prevent SARS-CoV-2 from Infecting Human Cells
Type I Interferon Deficiency in Blood Could Be Hallmark of Severe COVID-19, Finds Study
Low-Dose Lung Radiation Therapy Improves Outcomes in Patients with COVID-19 Pneumonia
Russia’s Potential COVID-19 Vaccine Proven Safe and Well-Tolerated in First Clinical Trial
Oxford COVID-19 Vaccine Could Offer ‘Double Protection’ Against Novel Coronavirus
AI-Assisted Technology Platform to Be Used in Hunt for Most Effective COVID-19 Treatments
BD’s Point-of-Care COVID-19 Tests and Instruments to Help US Government Increase Testing Capacity
First-in-Class COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies Could Serve as Immunity Passport for Vaccine Developers
COVID-19 Vaccines Under Development Not Guaranteed to Work, Warns Merck CEO
COVID-19 Antibodies Last Only Months, Calling for Stronger and Longer Lasting Vaccine Protection
BioMérieux’s BIOFIRE Respiratory Panel 2.1 Plus with SARS-CoV-2 Receives CE Mark
Metagenomics to Help Develop Targeted Respiratory Pathogen Panel for Identifying SARS-CoV-2 and 250 Other Pathogens
Moderna’s COVID-19 Vaccine Phase 1 Data Shows Rapid and Strong Immune Responses Against SARS-CoV-2
Self-Cleaning Mask with Antimicrobial Technology Deactivates 99% of Coronavirus Suspension in Minutes
3M and MIT Researchers Developing Low-Cost COVID-19 Diagnostic Test that Delivers Highly Accurate Results in Minutes
Dynavax Doses First Participants in Phase 1 Trial of Medicago’s Plant-Derived COVID-19 Vaccine
China’s Fosun Pharma Receives Acceptance Notice of Application for Clinical Trial of BioNTech’s mRNA COVID-19 Vaccine
FDA Identifies Specific Areas on Spike Protein of SARS-CoV-2 as Key Target for COVID-19 Vaccines
